Newsletter

June 2020 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: June Scorecard Number of Signals 24 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 16% Other stats: Number of signals over $10/share 14 Number […]

0Comments

Ekso Bionics Receives FDA Clearance of Robotic Exoskeleton for Acquired Brain Injuries

Ekso Bionics Holdings, Inc. (EKSO) announced on June 25 that it received 501(k) clearance from the FDA to market its EksoNRTM robotic exoskeleton to patients with acquired brain injuries. The FDA previously cleared EksoNR for stroke and spinal cord injury rehabilitation in 2016, and it is the first such device cleared for use in patients with […]

0Comments

FDA Approves Lilly’s New Rapid-Acting Insulin, Lyumjev

On June 15, the FDA approved Eli Lilly and Company’s (LLE) new drug, Lyumjev™. It is a new rapid-acting form of insulin designed to speed the absorption of insulin into the blood stream and resduce A1C levels. Lyumjev is a novel formulation of insulin lispro that controls high blood sugar after meals in adults with […]

0Comments

May 2020 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: May Scorecard Number of Signals 22 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 9% Other stats: Number of signals over $10/share 15 Number […]

0Comments

Argenx Reports Positive Phase 3 Clinical Trial Results

On May 26, argenx (ARGX) reported positive Phase 3 clinical trial results from the ADAPT trial of efgartigimod. The ADAPT trial evaluates improvement in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score for acetylcholine receptor-antibody positive (AChR-Ab+) generalized myasthenia gravis (gMG) patients. Respondents in the trial saw an improvement of at least two points […]

0Comments

Ultragenyx Reports Positive Initial Data on DTX401 Clinical Trial

On May 15, Ultragenyx Pharmaceutical Inc. (RARE) presented positive initial data from all three cohorts in its DTX401 clinical trial. DTX401 is an adeno-associated virus-based gene therapy. It is undergoing clinical trials for the treatment of glycogen storage disease type 1a (GSD1a). All patients demonstrated significant cornstarch reductions over time and increases in time to […]

0Comments

April 2020 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: April Scorecard Number of Signals 12 Percent Correct – Prev Close to 5-day Peak 92% Avg Increase – Next open to 5-day Peak 9% Other stats: Number of signals over $10/share 9 Number […]

0Comments

Akebia Announces Positive Phase 3 Clinical Trial Results

Akebia Therapeutics, Inc. (AKBA) announced positive top-line results on May 5 for the first of its two Phase 3 cardiovascular outcomes programs. The two INNO2VATE studies evaluated the efficacy and safety of Akebia’s drug vadadustat. The drug treats anemia due to chronic kidney disease in adult patients on kidney dialysis. The studies indicate that the treatment […]

0Comments

March 2020 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: March Scorecard Number of Signals 13 Percent Correct – Prev Close to 5-day Peak 77% Avg Increase – Next open to 5-day Peak 5% Other stats: Number of signals over $10/share 6 Number […]

0Comments

February 2020 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: February Scorecard Number of Signals 13 Percent Correct – Prev Close to 5-day Peak 85% Avg Increase – Next open to 5-day Peak 12% Other stats: Number of signals over $10/share 7 Number […]

0Comments